Showing results (161-170 of 180) with videos related to
Sort By:
Pageof 18
The Lancet. Oncology|September 27, 2020
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trialMariano Provencio, Ernest Nadal, Amelia Insa, et al.The New England Journal of Medicine|September 9, 2017
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung CancerScott J Antonia, Augusto Villegas, Davey Daniel, et al.Journal for Immunotherapy of Cancer|October 20, 2024
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancerMarta Molina-Alejandre, Francisco Perea, Virginia Calvo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2021
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung CancerHossein Borghaei, Scott Gettinger, Everett E Vokes, et al.Clinical and Translational Medicine|July 29, 2021
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trialRaquel Laza-Briviesca, Alberto Cruz-Bermúdez, Ernest Nadal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2022
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)Mariano Provencio, Roberto Serna-Blasco, Ernest Nadal, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant ChemoimmunotherapyMarta Casarrubios, Alberto Cruz-Bermúdez, Ernest Nadal, et al.The New England Journal of Medicine|October 4, 2018
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCScott J Antonia, Augusto Villegas, Davey Daniel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2026
Decoding B Cell Signatures of Complete Pathological Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung CancerBelén Sierra-Rodero, Ángeles Gil-González, Marta Molina-Alejandre, et al.The New England Journal of Medicine|June 28, 2023
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung CancerMariano Provencio, Ernest Nadal, José L González-Larriba, et al.Pageof 18